2013-10-23T08:27:15-05:00 2012-12-31 KULLMAN SIEBERT LLC 1997 ANNAPOLIS EXCHANGE PKWY STE 51 ANNAPOLIS MD 214013275 990 2012-01-01 270486705 ALLIANCE FOR REGENERATIVE MEDICINE ALLI 2024192515 525 SECOND STREET NE WASHINGTON DC 20002 EDWARD L FIELD 2024192515 2013-10-02 true STEPHEN J KULLMAN CPA 4102669885 2013-10-02 2012 2016-02-24 21:20:13Z GIL VAN BOKKELEN 525 SECOND STREET NE WASHINGTON DC 20002 1615866 false X WWW.ALLIANCERM.ORG X 2009 DC TO EDUCATE KEY POLICY MAKERS ABOUT THE POTENTIAL OF REGENERATIVE MEDICINE AND TO ADVOCATE FOR FAVORABLE PUBLIC POLICIES - FUNDING, REGULATORY, REIMBURSEMENT AND OTHERS AND TO FACILITATE ADVANCES IN THE FIELD 20 20 0 43 0 168900 55750 1051615 1560017 173 99 0 1220688 1615866 0 0 0 0 0 1039023 1470975 1039023 1470975 181665 144891 526986 516489 196150 38172 330836 478317 X TO EDUCATE KEY POLICY MAKERS ABOUT THE POTENTIAL OF REGENERATIVE MEDICINE AND TO ADVOCATE FOR FAVORABLE PUBLIC POLICIES - FUNDING, REGULATORY, REIMBURSEMENT AND OTHERS AND TO FACILITATE ADVANCES IN THE FIELD false false 558215 POLICY, ADVOCACY AND GOVERNMENT RELATIONS ACTIVITIES AND ACCOMPLISHMENTS INCLUDE, BUT ARE NOT LIMITED TO: A. GOVERNMENT RELATIONS: RMPA/STRATEGIC ASSESSMENT/NATIONAL STRATEGY; PATIENT ADVOCACY GROUP OUTREACH; LEGISLATIVE DAY AND FLY-IN ACTIVITIES; RM NATIONAL STRATEGY WORKSHOP; AFIRM REAUTHORIZATION/DEPARTMENT OF DEFENSE; PDUFA ADVOCACY SUPPORT. B. REGULATORY: INTERNATIONAL REGULATORY WORKSHOP - HARMONIZATION; FDA COMMUNICATIONS WHITE PAPER; MEETINGS WITH FDA/PARTICIPATION IN REGULATORY PROCESS/COMMENTS FILED; ARM FDA WORKSHOP; TASK FORCE ON ANIMAL MODELS; DEVELOPMENT OF REGULATORY MATRIX/ROADMAP TO ASSIST MEMBERS WITH REGULATORY DECISION MAKING. C. REIMBURSEMENT: PHARMACO-ECONOMIC STUDIES IN KEY THERAPEUTIC AREAS; WHITE PAPER ON PRODUCTS IN DEVELOPMENT - UNIQUE REIMBURSEMENT ISSUES; FUNDING TO SUPPORT PROJECTS FROM CMS, AHRQ, AND PCORI MEETINGS; PRIVATE INSURERS - WORKSHOP SERIES; CATALOGING AND IDENTIFYING CLINICAL KOLS BY DISEASE AREA. 558215 COMMUNICATIONS, CAPITAL FORMATION, OPERATIONS ACTIVITIES AND ACCOMPLISHMENTS INCLUDE, BUT ARE NOT LIMITED TO: A. COMMUNICATIONS: DEVELOPMENT OF ANNUAL INDUSTRY REPORT; WEBSITE UPGRADE - WITH KEY MEMBER INTERACTION FEATURES; WEBSITE MAINTENANCE; PUBLICATION OF BI-WEEKLY NEWSLETTER FOR RM COMMUNITY; SOCIAL MEDIA STRATEGY FOR POLITICAL AGENDA AND INVESTOR OUTREACH; PUBLIC RELATIONS AND MARKETING; CULTIVATION OF RELATIONSHIPS WITH PRESS AND MEDIA; DEVELOPMENT OF MATERIALS TO EDUCATE THE PUBLIC ABOUT RM. B. CAPITAL FORMATION: NEW YORK INVESTOR MEETING; VENTURE/DIRECTED PHILANTHROPY FUND; FEDERAL FUNDING OPPORTUNITIES FOR RM IDENTIFICATION PROJECT; DEVELOPMENT OF MASTER CONTACT LIST OF INVESTORS AND KEY PHARMA CONTACTS FOR MEMBERS. C. OPERATIONS AND GOVERNANCE: UPDATE OF ALL MEMBERSHIP MATERIALS AND DEVELOPMENT OF NEW ONES; CONFERENCES AND EVENTS INCLUDING: STEM CELL MEETING ON THE MESA, CLINICAL OUTLOOKS IN REGENERATIVE, RM STATE OF THE INDUSTRY ADDRESS, ARM ANNUAL DINNER ADVANCED THERAPIES SUMMIT IN EUROPE; COSTS ASSOCIATED WITH BOARD, EXECUTIVE COMMITTEE AND STRATEGIC PLANNING MEETINGS; LAUNCH OF EUROPEAN CHAPTER - ALLIANCE FOR ADVANCED THERAPIES. 124048 SCIENCE AND TECHNOLOGY ACTIVITIES AND ACCOMPLISHMENTS INCLUDE, BUT ARE NOT LIMITED TO: A. POTENCY PROJECT; DEVELOP ON-LINE DATABASE AND DATA COLLECTION SYSTEM FOR MEMBERS TO ACCESS AND STAFF TO MAINTAIN POTENCY PROJECT INFORMATION; DEVELOPMENT OF ECONOMIC/BUSINESS MODEL TO MAINTAIN DATA RESOURCES AND REFERENCE STANDARD CELL BANK; WHITE PAPER ON NEXT INITIATIVE - STABILITY, GENOMIC MARKERS AND QC; COORDINATION WITH OTHER KEY STANDARDS ORGANIZATIONS - ISCT, ISSCR, ASTM, USP, NIST. OTHER ACTIVITIES INCLUDING: DISCUSSIONS WITH HEALTH CARE PROVIDERS TO ENSURE ADEQUATE COVERAGE OF REGENERATIVE MEDICINE PRODUCTS; PRESENTING INFORMATION AT PUBLIC MEETINGS CONVENED BY FDA AND NIH; PUBLISHING A BI- WEEKLY NEWSLETTER ENTITLED REGENERATIVE MEDICINE FORUM ALONG WITH THE GENETICS POLICY INSTITUTE; HELD ANNUAL MEETING IN WASHINGTON, D.C. 1240478 false true false true false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false false true false false false false false false false false true 8 0 0 false false false false true true false X 20 20 false false false false false false false true true false false false true true true false false false false false X X THOMAS J DULA 7038551301 525 SECOND STREET NE WASHINGTON DC 20002 X GIL VAN BOKKELEN 5.00 X X 0 0 0 ED FIELD 5.00 X X 0 0 0 LEONA BRENNER-GATI MD 5.00 X X 0 0 0 DEAN TOZER 5.00 X X 0 0 0 DR ANTHONY ATALA 5.00 X 0 0 0 MATTHEW VINCENT 5.00 X 0 0 0 RICHARD INSEL 5.00 X 0 0 0 DOUG DOERFLER 5.00 X 0 0 0 GARY GILLHEENEY 5.00 X 0 0 0 ROBERT SHAW 5.00 X 0 0 0 MARTIN MCGLYNN 5.00 X 0 0 0 MICHAEL SCHUSTER 5.00 X 0 0 0 KEITH MURPHY 5.00 X 0 0 0 ROBERT PRETI 5.00 X 0 0 0 DEVYN SMITH 5.00 X 0 0 0 MATTHIAS STEGER 5.00 X 0 0 0 BERNARD SIEGEL 5.00 X 0 0 0 SUSAN SOLOMON 5.00 X 0 0 0 ALAN TROUNSON 5.00 X 0 0 0 CHRIS CALHOUN 5.00 X 0 0 0 false false false ADJUVANT GLOBAL ADVISORS 3 BETHESDA METRO CENTER BETHESDA MD 20814 MANAGEMENT ADV 300000 HOLLAND AND KNIGHT LLP 7101 WISCONSIN AVE SUITE 1001 BETHESDA MD 20814 LEGAL 300000 2 55750 55750 MEMBERSHIP DUES 1239925 1239925 STEM CELL CONFERENCE 312935 312935 ANNUAL MEETING 7157 7157 1560017 99 99 1615866 1560017 99 X 300000 150000 150000 90000 90000 20338 20338 210000 210000 191138 191138 21221 21221 8938 8938 30000 30000 45699 45699 413368 413368 MEMBERSHIP SUPPORT 140273 140273 1470975 1240478 230497 0 210155 42812 109876 100052 206955 345913 2712 25000 526986 516489 196150 38172 196150 38172 X 330836 478317 330836 478317 526986 516489 144891 2590 X false false false RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false 1239925 210000 210000 371978 -161978 ADJUVANT GLOBAL ADVISORS RUFFIN & CONROY 300000 MANAGEMENT FEES false ADDITIONAL INFORMATION SCHEDULE L PART V SCHEDULE L PART IV BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS A NAME OF PERSON ADJUVANT GLOBAL ADVISORS B RELATIONSHIP BETWEEN INTERESTED PERSON AND ORGANIZATION EDMUND RUFFIN JEFF CONROY FORMER DIRECTORS EACH OWN 50 OF ADJUVANT GLOBAL ADVISORS D DESCRIPTION OF TRANSACTION MANAGEMENT FEES PAID TO ADJUVANT GLOBAL ADVISORS FIRST ACCOMPLISHMENT DESCRIPTION FORM 990, PAGE 2, PART III, LINE 4A C. REIMBURSEMENT: PHARMACO-ECONOMIC STUDIES IN KEY THERAPEUTIC AREAS; WHITE PAPER ON PRODUCTS IN DEVELOPMENT - UNIQUE REIMBURSEMENT ISSUES; FUNDING TO SUPPORT PROJECTS FROM CMS, AHRQ, AND PCORI MEETINGS; PRIVATE INSURERS - WORKSHOP SERIES; CATALOGING AND IDENTIFYING CLINICAL KOLS BY DISEASE AREA. SECOND ACCOMPLISHMENT DESCRIPTION FORM 990, PAGE 2, PART III, LINE 4B CONTACTS FOR MEMBERS. C. OPERATIONS AND GOVERNANCE: UPDATE OF ALL MEMBERSHIP MATERIALS AND DEVELOPMENT OF NEW ONES; CONFERENCES AND EVENTS INCLUDING: STEM CELL MEETING ON THE MESA, CLINICAL OUTLOOKS IN REGENERATIVE, RM STATE OF THE INDUSTRY ADDRESS, ARM ANNUAL DINNER ADVANCED THERAPIES SUMMIT IN EUROPE; COSTS ASSOCIATED WITH BOARD, EXECUTIVE COMMITTEE AND STRATEGIC PLANNING MEETINGS; LAUNCH OF EUROPEAN CHAPTER - ALLIANCE FOR ADVANCED THERAPIES. ALL OTHER ACCOMPLISHMENT DESCRIPTION FORM 990, PAGE 2, PART III, LINE 4D OTHER ACTIVITIES INCLUDING: DISCUSSIONS WITH HEALTH CARE PROVIDERS TO ENSURE ADEQUATE COVERAGE OF REGENERATIVE MEDICINE PRODUCTS; PRESENTING INFORMATION AT PUBLIC MEETINGS CONVENED BY FDA AND NIH; PUBLISHING A BI- WEEKLY NEWSLETTER ENTITLED REGENERATIVE MEDICINE FORUM ALONG WITH THE GENETICS POLICY INSTITUTE; HELD ANNUAL MEETING IN WASHINGTON, D.C. ORGANIZATION'S PROCESS USED TO REVIEW FORM 990 FORM 990, PAGE 6, PART VI, LINE 11B THE TREASURER REVIEWS THE TAX RETURN ALONG WITH THE OTHER OFFICERS OF THE ORGANIZATION PRIOR TO FILING ENFORCEMENT OF CONFLICTS POLICY FORM 990, PAGE 6, PART VI, LINE 12C THE CONFLICT OF INTEREST POLICY COVERS ANY DIRECTOR, PRINCIPAL OFFICER, OR MEMBER OF A COMMITTEE WITH GOVERNING BOARD DELEGATED POWERS. DISCLOSURE IS TO DIRECTORS AND MEMBERS OF COMMITTEES WITH GOVERNING BOARD DELEGATED POWERS. DISCLOSURES ARE REVIEWED AND MAINTAINED BY THE REMAINING MEMBERS OF THE GOVERNING BOARD OR COMMITTEE. THE GOVERNING BOARD OR COMMITTEE REVIEWS EACH TRANSACTION TO COME BEFORE THE BOARD FOR POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. IF POTENTIAL OR ACTUAL CONFLICTS (PAST, PRESENT OR FUTURE) ARE IDENTIFIED, THE CHAIRPERSON OF THE GOVERNING BOARD OR COMMITTEE SHALL, IF APPROPRIATE, APPOINT A DISINTERESTED PERSON OR COMMITTEE TO INVESTIGATE ALTERNATIVES TO THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER EXERCISING DUE DILIGENCE, THE GOVERNING BOARD OR COMMITTEE SHALL DETERMINE WHETHER ARM CAN OBTAIN WITH REASONABLE EFFORTS A MORE ADVANTAGEOUS TRANSACTION OR ARRANGEMENT FROM A PERSON OR ENTITY THAT WOULD NOT GIVE RISE TO A CONFLICT OF INTEREST. THE IDENTIFIED CONFLICTS OF INTEREST AND APPROPRIATE RECUSALS ARE DOCUMENTED IN THE MINUTES OF EACH BOARD OR COMMITTEE MEETING. GOVERNING DOCUMENTS DISCLOSURE EXPLANATION FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION DOES NOT MAKE ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC. OTHER FEES FOR SERVICES FORM 990, PART IX, LINE 11G 191,138 0 0